Your browser doesn't support javascript.
A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant.
Chang, Yi-Chung; Yang, Chi-Fan; Chen, Yi-Fen; Yang, Chia-Chun; Chou, Yuan-Lin; Chou, Hung-Wen; Chang, Tein-Yao; Chao, Tai-Ling; Hsu, Shu-Chen; Ieong, Si-Man; Tsai, Ya-Min; Liu, Ping-Cheng; Chin, Yuan-Fan; Fang, Jun-Tung; Kao, Han-Chieh; Lu, Hsuan-Ying; Chang, Jia-Yu; Weng, Ren-Shiuan; Tu, Qian-Wen; Chang, Fang-Yu; Huang, Kuo-Yen; Lee, Tong-Young; Chang, Sui-Yuan; Yang, Pan-Chyr.
  • Chang YC; Oneness Biotech Company Limited, Taipei, Taiwan.
  • Yang CF; Microbio (Shanghai) Biotech Company, Shanghai, China.
  • Chen YF; Oneness Biotech Company Limited, Taipei, Taiwan.
  • Yang CC; Microbio (Shanghai) Biotech Company, Shanghai, China.
  • Chou YL; Microbio (Shanghai) Biotech Company, Shanghai, China.
  • Chou HW; Oneness Biotech Company Limited, Taipei, Taiwan.
  • Chang TY; Institute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan.
  • Chao TL; Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Hsu SC; Institute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan.
  • Ieong SM; Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Tsai YM; Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Liu PC; Institute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan.
  • Chin YF; Institute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan.
  • Fang JT; Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Kao HC; Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Lu HY; Institute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan.
  • Chang JY; Institute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan.
  • Weng RS; Oneness Biotech Company Limited, Taipei, Taiwan.
  • Tu QW; Oneness Biotech Company Limited, Taipei, Taiwan.
  • Chang FY; Oneness Biotech Company Limited, Taipei, Taiwan.
  • Huang KY; Institute of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan.
  • Lee TY; Microbio (Shanghai) Biotech Company, Shanghai, China.
  • Chang SY; Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Yang PC; Department of Laboratory Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
EMBO Mol Med ; 14(4): e15298, 2022 04 07.
Article in English | MEDLINE | ID: covidwho-1675333
ABSTRACT
The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants has altered the trajectory of the COVID-19 pandemic and raised some uncertainty on the long-term efficiency of vaccine strategy. The development of new therapeutics against a wide range of SARS-CoV-2 variants is imperative. We, here, have designed an inhalable siRNA, C6G25S, which covers 99.8% of current SARS-CoV-2 variants and is capable of inhibiting dominant strains, including Alpha, Delta, Gamma, and Epsilon, at picomolar ranges of IC50 in vitro. Moreover, C6G25S could completely inhibit the production of infectious virions in lungs by prophylactic treatment, and decrease 96.2% of virions by cotreatment in K18-hACE2-transgenic mice, accompanied by a significant prevention of virus-associated extensive pulmonary alveolar damage, vascular thrombi, and immune cell infiltrations. Our data suggest that C6G25S provides an alternative and effective approach to combating the COVID-19 pandemic.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: EMBO Mol Med Journal subject: Molecular Biology Year: 2022 Document Type: Article Affiliation country: Emmm.202115298

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: EMBO Mol Med Journal subject: Molecular Biology Year: 2022 Document Type: Article Affiliation country: Emmm.202115298